BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

The data – presented in a keynote at the ESMO cancer congress – also showed a three-fold improvement in progression-free survival – 25.1 months for Enhertu versus 7.2 months for Roche's drug ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (SABCS ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Enhertu is a HER2-directed antibody-drug conjugate (ADC). Enhertu consists of a HER2 monoclonal antibody linked to multiple topoisomerase 1 inhibitor payloads, including the exatecan derivative DXd, ...

Results from the late-stage Destiny-Gastric04 study showed that Enhertu resulted in a “statistically significant and clinically meaningful improvement” in overall survival in patients with ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.